Novo Nordisk A/S (NVO)
40.65
-0.44
(-1.07%)
USD |
NYSE |
Nov 12, 16:00
40.84
+0.19
(+0.47%)
Pre-Market: 05:23
Novo Nordisk Price to Book Value : 5.430 for Nov. 12, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 5.430 |
| November 11, 2026 | 5.489 |
| November 10, 2026 | 5.437 |
| November 09, 2026 | 5.528 |
| November 06, 2026 | 5.385 |
| November 05, 2026 | 5.384 |
| November 04, 2026 | 5.635 |
| November 03, 2026 | 5.369 |
| November 02, 2026 | 5.404 |
| October 30, 2026 | 5.343 |
| October 29, 2026 | 5.228 |
| October 28, 2026 | 5.115 |
| October 27, 2026 | 5.166 |
| October 26, 2026 | 5.227 |
| October 23, 2026 | 5.216 |
| October 22, 2026 | 5.267 |
| October 21, 2026 | 5.218 |
| October 20, 2026 | 5.256 |
| October 19, 2026 | 5.132 |
| October 16, 2026 | 5.187 |
| October 15, 2026 | 5.239 |
| October 14, 2026 | 5.092 |
| October 13, 2026 | 5.084 |
| October 12, 2026 | 5.154 |
| October 09, 2026 | 5.162 |
| Date | Value |
|---|---|
| October 08, 2026 | 5.100 |
| October 07, 2026 | 5.111 |
| October 06, 2026 | 5.013 |
| October 05, 2026 | 5.015 |
| October 02, 2026 | 4.985 |
| October 01, 2026 | 4.996 |
| September 30, 2026 | 5.064 |
| September 29, 2026 | 5.004 |
| September 28, 2026 | 5.056 |
| September 25, 2026 | 5.068 |
| September 24, 2026 | 5.044 |
| September 23, 2026 | 4.986 |
| September 22, 2026 | 5.146 |
| September 21, 2026 | 5.199 |
| September 18, 2026 | 5.648 |
| September 17, 2026 | 5.641 |
| September 16, 2026 | 5.448 |
| September 15, 2026 | 5.555 |
| September 14, 2026 | 5.675 |
| September 11, 2026 | 5.626 |
| September 10, 2026 | 5.748 |
| September 09, 2026 | 5.820 |
| September 08, 2026 | 5.899 |
| September 04, 2026 | 6.087 |
| September 03, 2026 | 6.206 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| AstraZeneca PLC | 12.08 |
| GSK Plc | 4.074 |
| Johnson & Johnson | 8.371 |
| Eli Lilly & Co. | 33.36 |
| Merck & Co., Inc. | 8.075 |
Price to Book Value Related Metrics
| PE Ratio | 10.24 |
| PS Ratio | 3.477 |
| PEG Ratio | 0.6606 |
| Price to Free Cash Flow | 25.86 |
| Price | 40.65 |
| Earnings Yield | 9.77% |
| Market Cap | 136.01B |
| PEGY Ratio | 0.514 |
| Operating PE Ratio | 7.191 |
| Normalized PE Ratio | 9.244 |